%0 Journal Article
%T No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta
%A Amit Bar-Or
%A Anthony Traboulsee
%A Douglas L Arnold
%A Eva Havrdov¨¢
%A Fred Lublin
%A Gavin Giovannoni
%A Giancarlo Comi
%A Hans-Peter Hartung
%A Hideki Garren
%A Iain Bennett
%A Jian Han
%A Julie Napieralski
%A Krzysztof Selmaj
%A Laura Julian
%A Ludwig Kappos
%A Regine Buffels
%A Shibeshih Belachew
%A Stephen L Hauser
%J Multiple Sclerosis Journal
%@ 2055-2173
%D 2018
%R 10.1177/2055217318760642
%X No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. NEDA was assessed in a modified intent-to-treat population (n£¿=£¿1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN ¦Â©\1a; 44 ¦Ìg). NEDA was increased with ocrelizumab vs IFN ¦Â-1a over 96 weeks by 75% (p£¿<£¿0.001), from Week 0£¿24 by 33% (p£¿<£¿0.001) and from Week 24£¿96 by 72% (p£¿<£¿0.001). Among patients with disease activity during Weeks 0£¿24, 66.4% vs 24.3% achieved NEDA during Weeks 24£¿96 in the ocrelizumab and IFN ¦Â-1a groups (relative increase: 177%; p£¿<£¿0.001). Superior efficacy with ocrelizumab compared with IFN ¦Â-1a was consistently seen in maintaining NEDA status in all epochs evaluated. By contrast with IFN ¦Â-1a, the majority of patients with disease activity early in the study subsequently attained NEDA status with ocrelizumab
%K NEDA
%K disease activity
%K relapse
%K disability progression
%K MRI activity
%U https://journals.sagepub.com/doi/full/10.1177/2055217318760642